SwanMedica Oy started selling and marketing prescription drugs in 2016. On 16 December 2020, the Finnish Medicines Agency Fimea granted SwanMedica Oy a pharmaceutical wholesale license. For SwanMedia, this means an improved ability to provide pharmaceutical sales and marketing services to international partners. For Finnish doctors and patients, this means a wider range of medicines available in the future.
Until now, SwanMedica has been mainly involved in the sales and marketing of urological and neurological prescription drugs. We have not needed a pharmaceutical wholesale license so far, because our current principals have had their own wholesale licenses and distribution agreements.
The first prescription drug we will import will be a urological drug used to treat the signs and symptoms of benign prostatic hyperplasia. The molecule is new in the Nordic countries, but it has been used around the world for a long time.
“Our own pharmaceutical wholesale license enables a more diverse range of services for our international partners. In addition, we will be a more significant option in contract negotiations in the future.” says Juha Waisanen, Entrepreneur and Managing Director of SwanMedica Oy.
Vaissalo Consulting Oy acted as SwanMedica’s advisor with the wholesale license application. Oy Medifon Ab is SwanMedica’s pharmaceutical wholesaler in Finland.
SwanMedica’s promotion theme below translates to: “SwanMedica – supporting Finnish urology”.
For more information:
Tel. +358 17 369 00 33